Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
Stopped Study was terminated due to a strategic business decision and not due to safety concerns.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
- DRUG: EDP-938
- DRUG: Placebo
Sponsor
Enanta Pharmaceuticals, Inc